Surpassed $1 billion in annual sales in 2025, driven by record fourth-quarter pump shipments and double-digit growth in both U.S. and international markets. Management is fundamentally reshaping the business model by transitioning to a 'pay-as-you-go' (PayGo) reimbursement structure in the pharmacy channel to reduce patient out-of-pocket barriers. The shift to pharmacy is expected to double the lifetime revenue per patient while streamlining the prescription process for healthcare providers and improv ...

Internationally, Q4 sales grew 17% year over year to $80 million on 11,000 pump shipments, aided by growth in both pump and supply shipments. Vosseller noted favorable foreign exchange, offset by $4 million tied to the company’s transition to direct operations that primarily affected pump sales. For 2025, total distributor destocking and inventory buyback impact was about $7 million, below the company’s earlier estimate of $10 million due to a partial timing shift into the first quarter of 2026.In the fourt ...

Tandem Diabetes Care (NasdaqGM:TNDM) Q4 2025 Earnings call February 19, 2026 04:30 PM ET Company ParticipantsJoanne Wuensch - Managing DirectorJohn Sheridan - President and CEOJon Block - Managing DirectorLeigh Vosseller - EVP and CFOMathew Blackman - Managing DirectorMatt Taylor - Managing DirectorMike Kratky - Senior Managing Director of Medical Devices and Technology Equity ResearchShaymus Contorno - Equity Research AssociateSusan Morrison - EVP and Chief Administrative OfficerTravis Steed - Managing Dir ...

Tandem Diabetes Care (NasdaqGM:TNDM) Q4 2025 Earnings call February 19, 2026 04:30 PM ET Company ParticipantsJoanne Wuensch - Managing DirectorJohn Sheridan - President and CEOJon Block - Managing DirectorLeigh Vosseller - EVP and CFOMathew Blackman - Managing DirectorMatt Taylor - Managing DirectorMike Kratky - Senior Managing Director of Medical Devices and Technology Equity ResearchShaymus Contorno - Equity Research AssociateSusan Morrison - EVP and Chief Administrative OfficerTravis Steed - Managing Dir ...

Tandem Diabetes Care (NasdaqGM:TNDM) Q4 2025 Earnings call February 19, 2026 04:30 PM ET Speaker12Good day, and thank you for standing by. Welcome to the Tandem Diabetes Care Fourth Quarter 2025 Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question-and-answer session. To ask a question during the session, you will need to press star one one on your telephone. You will then hear an automated message advising your hand is ...

Core Viewpoint - Abbott Laboratories has initiated a recall in the United States for specific FreeStyle Libre 3 and FreeStyle Libre 3 Plus glucose monitoring sensors due to internal testing revealing certain issues [1] Group 1 - The recall affects certain models of the FreeStyle Libre 3 and FreeStyle Libre 3 Plus glucose monitoring sensors [1] - Internal testing conducted by the company indicated that some sensors may not perform as expected [1] - The company is taking corrective actions to address the identified issues with the sensors [1]

Company Overview - Abbott Laboratories has launched its FreeStyle Libre 3 Plus sensor for diabetes management in Canada, featuring the world's smallest glucose sensor, which is expected to enhance the company's Diabetes Care business [1][8] - The FreeStyle Libre system has achieved global leadership in continuous glucose monitoring (CGM) for both Type 1 and Type 2 diabetes users, contributing positively to Abbott's market sentiment [3][8] Financial Performance - Abbott's market capitalization stands at $231.78 billion, with an earnings yield of 3.9%, significantly higher than the industry average of 0.6% [4] - Over the past year, Abbott's shares have increased by 29.3%, outperforming the industry growth of 11.6% [10] Product Significance - The FreeStyle Libre 3 Plus simplifies glucose monitoring, allowing users to track glucose levels in real-time via a smartphone app, which is crucial for effective diabetes management [5][6] - Approximately 12 million Canadians live with diabetes, with around 90% having Type 2 diabetes, highlighting the importance of glucose monitoring in this demographic [5] Industry Prospects - The global CGM devices market is projected to reach $7.51 billion by 2030, growing at a CAGR of 7.19% from 2024 to 2030, driven by the rising prevalence of diabetes and increasing demand for treatment [7]